

Anti-PD-1 (Sintilimab), Human IgG4 Antibody

06/20

CATALOG NO.: A2156-100 (100 µg)

BACKGROUND DESCRIPTION: The research-grade biosimilar is a fully human IgG4 monoclonal antibody that targets the human cell surface receptor programmed cell death-1 (PD-1), an immune checkpoint protein with neoplastic functions. The antibody binds to PD-1 and prevents the association with its ligands PD-L1 and PD-L2. This results in inhibition of PD-1 and its downstream signaling, leading to the activation of T-cells and T-cell mediated immune response to inhibit tumor growth. The original drug is approved in China to treat relapsed or refractory patients with classic Hodgkin's lymphoma, after the second-line of chemotherapy. Currently, this drug is in the process of FDA approval for use in the United States. The drug is undergoing clinical trials to test for safety and efficacy in the treatment of cancers such as non-small cell lung cancer and esophageal cancer

ALTERNATE NAMES: IBI-308, PDCD1, PD1, CD279

ANTIBODY TYPE: Monoclonal

CONCENTRATION: 1 mg/ml

HOST/ISOTYPE: Recombinant / IgG4, kappa

SOURCE: CHO cells

IMMUNOGEN: Human PD-1

PURIFICATION: Protein A purified

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80°C

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-1 (Camrelizumab), Humanized Antibody (A2132)
 Anti-PD-1 (Spartalizumab), Humanized Antibody (A2131)
 Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)

FOR RESEARCH USE ONLY! Not to be used on humans.